New shot aims to reawaken Cancer-Fighting cells
NCT ID NCT07261657
Summary
This early safety study tests an immunotherapy drug called N-803 in patients with two rare types of soft tissue sarcoma. The participants have already been treated with a personalized cell therapy, but their cancer has started to grow again. Researchers want to see if N-803 can safely stimulate the remaining cancer-fighting cells from the prior treatment to work better against the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.